Sodium lactate
Osmoprep, Phosphates (sodium lactate) is a small molecule pharmaceutical. Sodium lactate was first approved as Sodium phosphates in plastic container on 1983-05-10. It is used to treat acidosis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Combinations
Osmoprep, Phosphates (generic drugs available since 2011-12-30, discontinued: Visicol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sodium phosphate
+
dibasic
+
anhydrous
+
Sodium phosphate
+
monobasic
+
monohydrate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
OSMOPREP | Salix Pharmaceuticals | N-021892 RX | 2006-03-16 | 1 products, RLD, RS |
Show 1 discontinued
Sodium phosphate
+
dibasic
+
heptahydrate
+
Sodium phosphate
+
monobasic
+
anhydrous
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SODIUM PHOSPHATES IN PLASTIC CONTAINER | Hospira | N-018892 RX | 1983-05-10 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
lactated ringers | New Drug Application | 2022-09-07 |
osmoprep | New Drug Application | 2019-03-04 |
potassium phosphates | unapproved drug other | 2022-07-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
acidosis | EFO_1000014 | D000138 | E87.2 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Sodium Phosphate, Dibasic, Anhydrous / Sodium Phosphate, Monobasic, Monohydrate, Osmoprep, Salix Pharms | |||
7687075 | 2028-06-22 | DS, DP |
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
936 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 23 | 43 | 6 | 1 | 5 | 69 | |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 12 | 5 | 22 | 1 | 3 | 43 |
Neoplasms | D009369 | C80 | 12 | 9 | 3 | 1 | 3 | 24 | |
Human influenza | D007251 | EFO_0007328 | J11.1 | 4 | 7 | 4 | 3 | 1 | 18 |
Acne vulgaris | D000152 | EFO_0003894 | L70 | 4 | 1 | 5 | 6 | 1 | 16 |
Hyperphosphatemia | D054559 | HP_0002905 | — | 1 | 4 | 3 | 6 | 13 | |
Postoperative pain | D010149 | G89.18 | — | 1 | 1 | 4 | 4 | 10 | |
Malaria | D008288 | EFO_0001068 | B54 | 6 | 1 | — | 2 | — | 8 |
Covid-19 | D000086382 | U07.1 | 2 | 3 | — | 2 | 2 | 8 | |
Falciparum malaria | D016778 | EFO_0007444 | B50 | 2 | 3 | 1 | 3 | — | 8 |
Show 60 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelodysplastic syndromes | D009190 | D46 | 51 | 97 | 8 | — | 14 | 149 | |
Leukemia | D007938 | C95 | 37 | 83 | 13 | — | 10 | 122 | |
Lymphoma | D008223 | C85.9 | 27 | 61 | 4 | — | 15 | 96 | |
Myeloid leukemia acute | D015470 | C92.0 | 42 | 58 | 5 | — | 5 | 95 | |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 29 | 43 | 4 | — | 4 | 72 | |
Non-hodgkin lymphoma | D008228 | C85.9 | 20 | 36 | 1 | — | 5 | 54 | |
Multiple myeloma | D009101 | C90.0 | 19 | 31 | 2 | — | 6 | 52 | |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 10 | 33 | 2 | — | 3 | 43 | |
Hodgkin disease | D006689 | C81 | 13 | 26 | 4 | — | 4 | 41 | |
Large b-cell lymphoma diffuse | D016403 | C83.3 | 12 | 21 | 2 | — | 3 | 33 |
Show 90 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Plasma cell neoplasms | D054219 | 14 | 28 | — | — | 6 | 44 | ||
Melanoma | D008545 | 12 | 17 | — | — | — | 27 | ||
Burkitt lymphoma | D002051 | C83.7 | 6 | 14 | — | — | 3 | 21 | |
B-cell lymphoma marginal zone | D018442 | C88.4 | 7 | 11 | — | — | 4 | 20 | |
Primary myelofibrosis | D055728 | D47.4 | 5 | 11 | — | — | 2 | 18 | |
Large-cell lymphoma anaplastic | D017728 | C84.6 | 5 | 13 | — | — | 3 | 18 | |
Large-cell lymphoma immunoblastic | D016400 | 5 | 11 | — | — | 3 | 17 | ||
Lymphomatoid granulomatosis | D008230 | C83.8 | 4 | 11 | — | — | 3 | 16 | |
Extranodal nk-t-cell lymphoma | D054391 | C86.0 | 4 | 10 | — | — | 3 | 15 | |
Myeloid leukemia accelerated phase | D015465 | 2 | 11 | — | — | 3 | 15 |
Show 119 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Plasmacytoma | D010954 | C90.3 | 1 | — | — | — | 1 | 2 | |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | 1 | 2 |
Rickets | D012279 | EFO_0005583 | E55.0 | 1 | — | — | — | 1 | 2 |
Hepatic insufficiency | D048550 | 2 | — | — | — | — | 2 | ||
Gram-positive bacterial infections | D016908 | 2 | — | — | — | — | 2 | ||
Dengue | D003715 | A90 | 2 | — | — | — | — | 2 | |
Depression | D003863 | F33.9 | 2 | — | — | — | — | 2 | |
Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | 1 | — | — | — | — | 1 |
Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | 1 | — | — | — | — | 1 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
Show 25 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperlactatemia | D065906 | — | — | — | — | 2 | 2 | ||
Sars-cov-2 | D000086402 | — | — | — | — | 2 | 2 | ||
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 2 | 2 |
Sinus floor augmentation | D059546 | — | — | — | — | 2 | 2 | ||
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 2 | 2 |
Papillomaviridae | D027383 | — | — | — | — | 1 | 1 | ||
Dermatitis | D003872 | HP_0011123 | L30.9 | — | — | — | — | 1 | 1 |
Sexual behavior | D012725 | — | — | — | — | 1 | 1 | ||
Hypertrophic cicatrix | D017439 | L91.0 | — | — | — | — | 1 | 1 | |
Cicatrix | D002921 | HP_0100699 | L90.5 | — | — | — | — | 1 | 1 |
Show 39 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | SODIUM LACTATE |
INN | compound solution of sodium lactate |
Description | Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste. It is produced by fermentation of a sugar source, such as corn or beets, and then, by neutralizing the resulting lactic acid to create a compound having the formula NaC3H5O3.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(O)C(=O)[O-].[Na+] |
Identifiers
PDB | — |
CAS-ID | 72-17-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1357 |
ChEBI ID | 75228 |
PubChem CID | 6286 |
DrugBank | — |
UNII ID | TU7HW0W0QT (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 92,216 documents
View more details
Safety
Black-box Warning
Black-box warning for: Osmoprep
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
936 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more